Author:
Zimmer Kai,Kocher Florian,Puccini Alberto,Seeber Andreas
Abstract
Mutated germline alleles in the DNA damage repair (DDR) genes “breast cancer gene 1” (BRCA1) and BRCA2 have originally been identified as major susceptibility genes in breast and ovarian cancers. With the establishment and approval of more cost-effective gene sequencing methods, germline and somatic BRCA mutations have been detected in several cancers. Since the approval of poly (ADP)-ribose polymerase inhibitors (PARPi) for BRCA-mutated cancers, BRCA mutations gained rising therapeutic implications. The impact and significance of BRCA mutations have been evaluated extensively in the last decades. Moreover, other genes involved in the DDR pathway, such as ATM, ATR, or CHK1, have emerged as potential new treatment targets, as inhibitors of these proteins are currently under clinical investigation. This review gives a concise overview on the emerging clinical implications of mutations in the DDR genes in gastrointestinal cancers with a focus on BRCA mutations.
Reference157 articles.
1. Estimates of the Gene Frequency of BRCA1 and Its Contribution to Breast and Ovarian Cancer Incidence;Ford;Am J Hum Genet,1995
2. Prevalence of BRCA1 Mutation Carriers Among U.S. Non-Hispanic Whites;Whittemore;Cancer Epidemiol Biomarkers Prev,2004
3. Average Risks of Breast and Ovarian Cancer Associated With BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies;Antoniou;Am J Hum Genet,2003
4. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers;Kuchenbaecker;JAMA,2017
5. Meta-Analysis of BRCA1 and BRCA2 Penetrance;Chen;J Clin Oncol,2007
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献